Success Metrics

Clinical Success Rate
84.9%

Based on 107 completed trials

Completion Rate
85%(107/126)
Active Trials
15(8%)
Results Posted
45%(48 trials)
Terminated
19(11%)

Phase Distribution

Ph phase_2
59
33%
Ph not_applicable
30
17%
Ph phase_3
27
15%
Ph early_phase_1
7
4%
Ph phase_1
32
18%
Ph phase_4
21
12%

Phase Distribution

39

Early Stage

59

Mid Stage

48

Late Stage

Phase Distribution176 total trials
Early Phase 1First-in-human
7(4.0%)
Phase 1Safety & dosage
32(18.2%)
Phase 2Efficacy & side effects
59(33.5%)
Phase 3Large-scale testing
27(15.3%)
Phase 4Post-market surveillance
21(11.9%)
N/ANon-phased studies
30(17.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.3%

107 of 130 finished

Non-Completion Rate

17.7%

23 ended early

Currently Active

15

trials recruiting

Total Trials

177

all time

Status Distribution
Active(20)
Completed(107)
Terminated(23)
Other(27)

Detailed Status

Completed107
unknown25
Terminated19
Recruiting10
Active, not recruiting5
Withdrawn4

Development Timeline

Analytics

Development Status

Total Trials
177
Active
15
Success Rate
84.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 17 (4.0%)
Phase 132 (18.2%)
Phase 259 (33.5%)
Phase 327 (15.3%)
Phase 421 (11.9%)
N/A30 (17.0%)

Trials by Status

terminated1911%
withdrawn42%
not_yet_recruiting42%
suspended21%
completed10760%
active_not_recruiting53%
enrolling_by_invitation11%
recruiting106%
unknown2514%

Recent Activity

Clinical Trials (177)

Showing 20 of 177 trialsScroll for more
NCT05604586Not Applicable

Assessment of the Impact of N-acetylcysteine Supplementation on Physical Performance

Completed
NCT02750319Phase 3

Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery

Active Not Recruiting
NCT04278898Phase 2

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose

Recruiting
NCT05494398Phase 2

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label

Enrolling By Invitation
NCT05610072Early Phase 1

Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)

Completed
NCT05537220Phase 3

Oral N-acetylcysteine for Retinitis Pigmentosa

Active Not Recruiting
NCT04374461Phase 2

A Study of N-acetylcysteine in Patients With COVID-19 Infection

Active Not Recruiting
NCT04520139Phase 1

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

Not Yet Recruiting
NCT03652753Phase 4

Pilon Fracture With Intra-articular Injection of N-Acetylcysteine (Pilon NAC)

Recruiting
NCT00775476Phase 2

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Active Not Recruiting
NCT07543458Phase 3

Therapeutics for Moderate and Severe Dengue

Not Yet Recruiting
NCT05142735Not Applicable

Effects of NAC on Symptoms of CHR Patients

Recruiting
NCT07464886Phase 3

Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth

Recruiting
NCT05123365Phase 1

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Recruiting
NCT06260566Phase 1

Tolerability of Enteral NAC in Infants

Not Yet Recruiting
NCT02583672Phase 2

Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

Completed
NCT05241262Phase 1

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

Recruiting
NCT05294744Not Applicable

Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)

Recruiting
NCT06377410Not Applicable

Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients

Recruiting
NCT01467466Phase 3

Prevention of Serious Adverse Events Following Angiography

Completed

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
177